CoChat

Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors

Francque, Sven, Szabo, Gyongyi, Abdelmalek, Manal F., Byrne, Christopher D., Cusi, Kenneth, Dufour, Jean-François, Roden, Michael, Sacks, Frank, Tacke, Frank · 2021 · Nature Reviews Gastroenterology & Hepatology

The DOI matches its Crossref record; 234 of the 235 references it cites were found in a registry or an index.

Abstract

The increasing epidemic of obesity worldwide is linked to serious health effects, including increased prevalence of type 2 diabetes mellitus, cardiovascular disease and nonalcoholic fatty liver disease (NAFLD). NAFLD is the liver manifestation of the metabolic syndrome and includes the spectrum of liver steatosis (known as nonalcoholic fatty liver) and steatohepatitis (known as nonalcoholic steatohepatitis), which can evolve into progressive liver fibrosis and eventually cause cirrhosis. Although NAFLD is becoming the number one cause of chronic liver diseases, it is part of a systemic disease that affects many other parts of the body, including adipose tissue, pancreatic β-cells and the cardiovascular system. The pathomechanism of NAFLD is multifactorial across a spectrum of metabolic derangements and changes in the host microbiome that trigger low-grade inflammation in the liver and other organs. Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear regulatory factors that provide fine tuning for key elements of glucose and fat metabolism and regulate inflammatory cell activation and fibrotic processes. This Review summarizes and discusses the current literature on NAFLD as the liver manifestation of the systemic metabolic syndrome and focuses on the role of PPARs in the pathomechanisms as well as in the potential targeting of disease.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41575-020-00366-5

Cites

234 of 234 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 234 references

Research works printed but not linked: 3

  1. CymaBay Therapeutics. CymaBay Therapeutics reports topline 12-week data from an ongoing phase 2b study of seladelpar in patients with nonalcoholic steatohepatitis. CymaBay https://ir.cymabay.com/press-releases?year=2019&page=2 (2019).
  2. CymaBay Therapeutics. CymaBay Therapeutics halts clinical development of seladelpar. CymaBay https://ir.cymabay.com/press-releases?year=2019&page=1 (2019).
  3. Bril, F. et al. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 42, 1481–1488 (2019). · DOI · Paper page

Cited by

See all 316

Metadata

Authors
Francque, S., Szabo, G., Abdelmalek, M. F., Byrne, C. D., Cusi, K., Dufour, J.-F., Roden, M., Sacks, F., & Tacke, F.
Affiliations
  • University of Antwerp (BE)
  • Duke University (US)
  • University Hospital Southampton NHS Foundation Trust (GB)
  • University of Florida Health (US)
  • University Hospital of Bern (CH)
  • Deutsches Diabetes-Zentrum e.V. (DE)
  • Brigham and Women's Hospital (US)
  • Charité – Universitätsmedizin Berlin (DE)
Corresponding author
Francque, Sven
Venue
Nature Reviews Gastroenterology & Hepatology
Published
2020-10-22
Volume
18
Issue
1
Pages
24-39
ISSN
  • 1759-5045 (ISSN-L)
  • 1759-5053
OpenAlex
W3094033262
Cited by
316
References
235
Citations by year
2026: 38 · 2025: 41 · 2024: 62 · 2023: 62 · 2022: 70 · 2021: 41 · 2020: 2
FWCI
6.38
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Reviews Gastroenterology & Hepatology (publishedVersion)
  • PubMed (publishedVersion)
  • ePrints Soton (University of Southampton) (acceptedVersion)
  • BORIS (University Library Bern) (submittedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords
nonalcoholic steatohepatitis, peroxisome proliferator-activated receptors, non-alcoholic fatty liver disease, metabolic syndrome, obesity, type 2 diabetes, liver fibrosis, PPAR agonists, gut microbiota
MeSH terms
Humans, Inflammation, Obesity, Disease Progression, Metabolic Syndrome, Peroxisome Proliferator-Activated Receptors, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. https://app.cochat.ai/papers/10.1038/s41575-020-00366-5
The paper
Francque, S., Szabo, G., Abdelmalek, M. F., Byrne, C. D., Cusi, K., Dufour, J.-F., Roden, M., Sacks, F., & Tacke, F. (2021). Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. Nature Reviews Gastroenterology & Hepatology. https://doi.org/10.1038/s41575-020-00366-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.